1. Home
  2. PHGE vs GELS Comparison

PHGE vs GELS Comparison

Compare PHGE & GELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • GELS
  • Stock Information
  • Founded
  • PHGE 2015
  • GELS 2018
  • Country
  • PHGE Israel
  • GELS Australia
  • Employees
  • PHGE N/A
  • GELS N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • GELS
  • Sector
  • PHGE Health Care
  • GELS
  • Exchange
  • PHGE Nasdaq
  • GELS NYSE
  • Market Cap
  • PHGE 13.3M
  • GELS 8.7M
  • IPO Year
  • PHGE N/A
  • GELS 2024
  • Fundamental
  • Price
  • PHGE $0.56
  • GELS $1.48
  • Analyst Decision
  • PHGE Strong Buy
  • GELS
  • Analyst Count
  • PHGE 2
  • GELS 0
  • Target Price
  • PHGE $23.00
  • GELS N/A
  • AVG Volume (30 Days)
  • PHGE 51.4K
  • GELS 4.7M
  • Earning Date
  • PHGE 05-15-2025
  • GELS 02-15-2025
  • Dividend Yield
  • PHGE N/A
  • GELS N/A
  • EPS Growth
  • PHGE N/A
  • GELS N/A
  • EPS
  • PHGE N/A
  • GELS N/A
  • Revenue
  • PHGE N/A
  • GELS $95,618.00
  • Revenue This Year
  • PHGE N/A
  • GELS N/A
  • Revenue Next Year
  • PHGE N/A
  • GELS N/A
  • P/E Ratio
  • PHGE N/A
  • GELS N/A
  • Revenue Growth
  • PHGE N/A
  • GELS N/A
  • 52 Week Low
  • PHGE $0.48
  • GELS $0.77
  • 52 Week High
  • PHGE $4.99
  • GELS $5.50
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 44.80
  • GELS N/A
  • Support Level
  • PHGE $0.54
  • GELS N/A
  • Resistance Level
  • PHGE $0.58
  • GELS N/A
  • Average True Range (ATR)
  • PHGE 0.04
  • GELS 0.00
  • MACD
  • PHGE 0.00
  • GELS 0.00
  • Stochastic Oscillator
  • PHGE 32.83
  • GELS 0.00

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About GELS GELTEQ LIMITED

Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.

Share on Social Networks: